Abstract
Cisplatin should be administered with diuretics and Magnesium supplementation under adequate hydration to avoid renal impairment. Patients should be evaluated for eGFR (estimated glomerular filtration rate) during the treatment with pemetrexed, as kidney injury has been reported. Pemetrexed should be administered with caution in patients with a CCr (creatinine clearance) < 45 mL/min. Mesna is used to prevent hemorrhagic cystitis in patients receiving ifosfamide. Febuxostat is effective in avoiding hyperuricemia induced by TLS (tumor lysis syndrome). Preventative rasburicase is recommended in high-risk cases of TLS. Thrombotic microangiopathy could be triggered by anticancer drugs and there is no evidence of efficacy of plasma exchange therapy. When proteinuria occurs during treatment with anti-angiogenic agents or multi-kinase inhibitors, dose reductions or interruptions based on grading should be considered. Grade 3 proteinuria and renal dysfunction require urgent intervention, including drug interruption or withdrawal, and referral to a nephrologist should be considered. The first-line drugs used for blood pressure elevation due to anti-angiogenic agents are ACE (angiotensin-converting enzyme) inhibitors and ARBs (angiotensin receptor blockers). The protein binding of drugs and their pharmacokinetics are considerably altered in patients with hypoalbuminemia. The clearance of rituximab is increased in patients with proteinuria, and the correlation with urinary IgG suggests similar pharmacokinetic changes when using other antibody drugs. AIN (acute interstitial nephritis) is the most common cause of ICI (immune checkpoint inhibitor)-related kidney injury that is often treated with steroids. The need for renal biopsy in patients with kidney injury that occurs during treatment with ICI remains controversial.
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs10147-023-02382-2/MediaObjects/10147_2023_2382_Fig1_HTML.png)
Similar content being viewed by others
References
Yanagita M (2023) Clinical questions and good practice statements in clinical practice guidelines for management of kidney injury during anticancer drug therapy 2022 (manuscript in submission)
(2021) Nippon Kayaku Co., Ltd. Full prescribing information for Randa® (in Japanese). https://mink.nipponkayaku.co.jp/product/di/te_file/sedi_rani_te.pdf
(2015) The Japan Lung Cancer Society, and Japanese Society of Medical Oncology, guideline for short hydration method in cisplatin administration, Aug 2015, [Japanese], https://www.haigan.gr.jp/uploads/files/photos/1022.pdf
Sasaki Y, Tamura T, Eguchi K et al (1989) Pharmacokinetics of (glycolate-0,0’)-diammine platinum(II), a new platinum derivative, in comparison with cisplatin and carboplatin. Cancer Chemother Pharmacol 23:243–246
Filipski KK, Mathijssen RH, Mikkelsen TS et al (2009) Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin Pharmacol Ther 86:396–402
Miller RP, Tadagavadi RK, Ramesh G et al (2010) Mechanisms of cisplatin nephrotoxicity. Toxins (Basel) 2:2490–2518
Horiuchi M, Inuyama Y, Kohno N et al (1982) Pharmacokinetics of Cis-dichlorodiammineplatinum (II) [Japanese]. Jpn J Cancer Chemother 9:632–637
Erdlenbruch B, Pekrum A, Roth C et al (2001) Cisplatin nephrotoxicity in children after continuous 72-h and 3x1-h infusions. Pediatr Nephrol 16:586–593
Lajer H, Daugaard G (1999) Cisplatin and hypomagnesemia. Cancer Treat Rev 25:47–58
Yokoo K, Murakami R, Matsuzaki T et al (2009) Enhanced renal accumulation of cisplatin via renal organic cation transporter deteriorates acute kidney injury in hypomagnesemic rats. Clin Exp Nephrol 13:578–584
Bodnar L, Wcislo G, Gasowska-Bodnar A et al (2008) Renal protection with magnesium subcarbonate and magnesium sulphate in patients with epithelial ovarian cancer after cisplatin and paclitaxel chemotherapy: a randomised phase II study. Eur J Cancer 44:2608–2614
Mita AC, Sweeney CJ, Baker SD et al (2006) Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function. J Clin Oncol 24:552–562
Visser S, Huisbrink J, van’t Veer NE et al (2018) Renal impairment during pemetrexed maintenance in patients with advanced nonsmall cell lung cancer: a cohort study. Eur Respir J 52:1800884
de Rouw N, Boosman RJ, van de Bruinhorst H et al (2020) Cumulative pemetrexed dose increases the risk of nephrotoxicity. Lung Cancer 146:30–35
Kawazoe H, Yano A, Ishida Y et al (2017) Non-steroidal anti-inflammatory drugs induce severe hematologic toxicities in lung cancer patients receiving pemetrexed plus carboplatin: A retrospective cohort study. PLoS ONE 12:e0171066
Nissim I, Horyn O, Daikhin Y et al (2006) Ifosfamide-induced nephrotoxicity: mechanism and prevention. Cancer Res 66:7824–7831
(2022) Shionogi & Co., Ltd. Interview Form for Ifomide® for Injection (in Japanese): https://www.shionogi.co.jp/med/download.php?h=0a54bf01fc13dae9174a669b0dbf1cee
Rossi R, Gödde A, Kleinebrand A et al (1994) Unilateral nephrectomy and cisplatin as risk factors of ifosfamide-induced nephrotoxicity: analysis of 120 patients. J Clin Oncol 12:159–165
Pratt CB, Meyer WH, Jenkins JJ et al (1991) Ifosfamide, Fanconi’s syndrome, and rickets. J Clin Oncol 9:1495–1499
Skinner R, Cotterill SJ, Stevens MC (2000) Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG Late Effects Group study. United Kingdom Children’s Cancer Study Group. Br J Cancer 82:1636–1645
Cairo MS, Coiffier B, Reiter A et al (2010) Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol 149:578–586
Spina M, Nagy Z, Ribera JM et al (2015) FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk. Ann Oncol 26:2155–2161
Tamura K, Kawai Y, Kiguchi T et al (2016) Efficacy and safety of febuxostat for prevention of tumor lysis syndrome in patients with malignant tumors receiving chemotherapy: a phase III, randomized, multi-center trial comparing febuxostat and allopurinol. Int J Clin Oncol 21:996–1003
Bellos I, Kontzoglou K, Psyrri A et al (2019) Febuxostat administration for the prevention of tumour lysis syndrome: a meta-analysis. J Clin Pharm Ther 44:525–533
Sircar D, Chatterjee S, Waikhom R et al (2015) Efficacy of febuxostat for slowing the GFR decline in patients with ckd and asymptomatic hyperuricemia: a 6-month, double-blind, randomized, placebo-controlled trial. Am J Kidney Dis 66:945–950
(2021) Japanese Society of Medical Oncology, Clinical Practice Guidelines for Tumor Lysis Syndrome [Japanese], 2nd edn. Kanehara-Shuppan Co. Ltd, Tokyo
Cortes J, Moore JO, Maziarz RT et al (2010) Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone—results of a multicenter phase III study. J Clin Oncol 28:4207–4213
Ishizawa K, Ogura M, Hamaguchi M et al (2009) Safety and efficacy of rasburicase (SR29142) in a Japanese phase II study. Cancer Sci 100:357–362
Allen KC, Champlain AH, Cotliar JA et al (2015) Risk of anaphylaxis with repeated courses of rasburicase: a research on adverse drug events and reports (RADAR) project. Drug Saf 38:183–187
Kagami S (2015) Clinical practice of Guidelines for atypical Hemolytic Uremic Syndrome (sHUS) 2015 [Japanese]. Jpns J Nephrol 58:62–75
Padmanabhan A, Connelly-Smith L, Aqui N et al (2019) Guidelines on the Use of Therapeutic Apheresis in Clinical practice—evidence-based approach from the Writing Committee of the American Society for apheresis: the eighth special issue. J Clin Apher 34:171–354
Glezerman I, Kris MG, Miller V et al (2009) Gemcitabine nephrotoxicity and hemolytic uremic syndrome: report of 29 cases from a single institution. Clin Nephrol 71:130–139
Widemann BC, Adamson PC (2006) Understanding and managing methotrexate nephrotoxicity. Oncologist 11:694–703
Mir O, Ropert S, Babinet A et al (2010) Hyper-alkalinization without hyper-hydration for the prevention of high-dose methotrexate acute nephrotoxicity in patients with osteosarcoma. Cancer Chemother Pharmacol 66:1059–1063
Ramsey LB, Balis FM, O’Brien MM et al (2018) Consensus guideline for use of glucarpidase in patients with high-dose methotrexate induced acute kidney injury and delayed methotrexate clearance. Oncologist 23:52–61
(2022) Ohara Pharmaceutical Co., Ltd. Interview form for Glucarpidase (Genetical Recombination) “Megludase® for Intravenous Use 1000” [Japanese] https://www.ohara-ch.co.jp/appendix/pdf/inc07/megludase-IF.pdf
Launay-Vacher V, Aapro M, De Castro Jr. G et al (2015) Renal effects of molecular targeted therapies in oncology: a review by the Cancer and the Kidney International Network (C-KIN). Ann Oncol 26:1677–1684
Muto S (2023) Chapter 1: Evaluation of kidney function in patients undergoing anticancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy. Int J Clin Oncol. https://doi.org/10.1007/s10147-023-02372-4
Izzedine H, Massard C, Spano JP et al (2010) VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management. Eur J Cancer 46:439–448
Zhang ZF, Wang T, Liu LH et al (2014) Risks of proteinuria associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a systematic review and meta-analysis. PLoS ONE 9:e90135
(2022) Japan Clinical Oncology Group, Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 [Japanese], http://www.jcog.jp/doctor/tool/CTCAEv5J_20220901_version.pdf
Wu S, Kim C, Baer L et al (2010) Bevacizumab increases risk for severe proteinuria in cancer patients. J Am Soc Nephrol 21:1381–1389
Zhu X, Wu S, Dahut WL et al (2007) Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 49:186–193
Wu S, Keresztes RS (2011) Antiangiogenic agents for the treatment of nonsmall cell lung cancer: characterizing the molecular basis for serious adverse events. Cancer Investig 29:460–471
Eremina V, Jefferson JA, Kowalewska J et al (2008) VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 358:1129–1136
Johnson DH, Fehrenbacher L, Novotny WF et al (2004) Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22:2184–2191
Maynard SE, Min JY, Merchan J et al (2003) Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Investig 111:649–658
Bollée G, Patey N, Cazajous G et al (2009) Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib. Nephrol Dial Transplant 24:682–685
George BA, Zhou XJ, Toto R (2007) Nephrotic syndrome after bevacizumab: case report and literature review. Am J Kidney Dis 49:e23-29
Overkleeft EN, Goldschmeding R, van Reekum F et al (2010) Nephrotic syndrome caused by the angiogenesis inhibitor sorafenib. Ann Oncol 21:184–185
Costero O, Picazo ML, Zamora P et al (2010) Inhibition of tyrosine kinases by sunitinib associated with focal segmental glomerulosclerosis lesion in addition to thrombotic microangiopathy. Nephrol Dial Transplant 25:1001–1003
Troxell ML, Higgins JP, Kambham N (2016) Antineoplastic treatment and renal injury: an update on renal pathology due to cytotoxic and targeted therapies. Adv Anat Pathol 23:310–329
(2022) AVASTIN® (bevacizumab) package insert, Chugai Pharmaceutical Co., Ltd. 4th edition (June, 2022). https://chugai-pharm.jp/content/dam/chugai/product/ava/div/pi/doc/ava_pi.pdf
Yeh J, Frieze D, Martins R et al (2010) Clinical utility of routine proteinuria evaluation in treatment decisions of patients receiving bevacizumab for metastatic solid tumors. Ann Pharmacother 44:1010–1015
Xu RH, Zhang Y, Pan H et al (2021) Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol 6:1015–1024
Kudo M, Finn RS, Qin S et al (2018) Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391:1163–1173
Patel TV, Morgan JA, Demetri GD et al (2008) A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib. J Natl Cancer Inst 100:282–284
Leeaphorn N, Kue APP, Thamcharoen N et al (2014) Prevalence of cancer in membranous nephropathy: a systematic review and meta-analysis of observational studies. Am J Nephrol 40:29–35
Zhao T, Wang X, Xu T et al (2017) Bevacizumab significantly increases the risks of hypertension and proteinuria in cancer patients: a systematic review and comprehensive meta-analysis. Oncotarget 8:51492–51506
Yamaguchi S, Murayama R, Satoh E et al (2021) Effects of tyrosine kinase inhibitors on blood pressure in patients with unresectable or advanced recurrent renal cell carcinoma-bayes-mixed treatment comparison meta-analysis. Gan To Kagaku Ryoho 48:1145–1151
Yeh ET, Bickford CL (2009) Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 53:2231–2247
Rini BI, Cohen DP, Lu DR et al (2011) Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 103:763–773
Zamorano JL, Lancellotti P, Rodriguez Muñoz D et al (2016) 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 37:2768–2801
Li M, Kroetz DL (2018) Bevacizumab-induced hypertension: clinical presentation and molecular understanding. Pharmacol Ther 182:152–160
Cameron AC, Touyz RM, Lang NN (2016) Vascular complications of cancer chemotherapy. Can J Cardiol 32:852–862
Izzedine H, Ederhy S, Goldwasser F et al (2009) Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol 20:807–815
Estrada CC, Maldonado A, Mallipattu SK (2019) Therapeutic inhibition of VEGF signaling and associated nephrotoxicities. J Am Soc Nephrol 30:187–200
Grenon NN (2013) Managing toxicities associated with antiangiogenic biologic agents in combination with chemotherapy for metastatic colorectal cancer. Clin J Oncol Nurs 17:425–433
Horsley L, Marti K, Jayson GC (2012) Is the toxicity of anti-angiogenic drugs predictive of outcome? A review of hypertension and proteinuria as biomarkers of response to anti-angiogenic therapy. Expert Opin Drug Metab Toxicol 8:283–293
Sorich MJ, Rowland A, Kichenadasse G et al (2016) Risk factors of proteinuria in renal cell carcinoma patients treated with VEGF inhibitors: a secondary analysis of pooled clinical trial data. Br J Cancer 114:1313–1317
Baek SH, Kim H, Lee J et al (2014) Renal adverse effects of sunitinib and its clinical significance: a single-center experience in Korea. Korean J Intern Med 29:40–48
Feliu J, Salud A, Safont MJ et al (2015) Correlation of hypertension and proteinuria with outcome in elderly bevacizumab-treated patients with metastatic colorectal cancer. PLoS ONE 10:e0116527
Izzedine H, Perazella MA (2015) Thrombotic microangiopathy, cancer, and cancer drugs. Am J Kidney Dis 66:857–868
Izzedine H, Mangier M, Ory V et al (2014) Expression patterns of RelA and c-mip are associated with different glomerular diseases following anti-VEGF therapy. Kidney Int 85:457–470
Izzedine H, Escudier B, Lhomme C et al (2014) Kidney diseases associated with anti-vascular endothelial growth factor (VEGF): an 8-year observational study at a single center. Medicine (Baltimore) 93:333–339
Gugler R, Shoeman DW, Huffman DH et al (1975) Pharmacokinetics of drugs in patients with the nephrotic syndrome. J Clin Investig 55:1182–1189
Reiss SN, Buie LW, Adel N et al (2016) Hypoalbuminemia is significantly associated with increased clearance time of high dose methotrexate in patients being treated for lymphoma or leukemia. Ann Hematol 95:2009–2015
Arrieta O, Michel Ortega RM, Villanueva-Rodríguez G et al (2010) Association of nutritional status and serum albumin levels with development of toxicity in patients with advanced non-small cell lung cancer treated with paclitaxel-cisplatin chemotherapy: a prospective study. BMC Cancer 10:50
Murdock JL, Duco MR, Reeves DJ (2021) Tolerability of highly protein bound targeted oral oncolytic drugs in patients with hypoalbuminemia: a retrospective analysis. Ann Pharmacother 55:165–173
McLean TW, Stewart RM, Curley TP et al (2020) Hypoalbuminemia in children with cancer treated with chemotherapy. Pediatr Blood Cancer 67:e28065
Takeuchi T, Miyasaka N, Inoue K et al (2009) Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study. Mod Rheumatol 19:478–487
Tout M, Casasnovas O, Meignan M et al (2017) Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association report. Blood 129:2616–2623
Tabernero J, Ohtsu A, Muro K et al (2017) Exposure-response analyses of ramucirumab from two randomized, phase III trials of second-line treatment for advanced gastric or gastroesophageal junction cancer. Mol Cancer Ther 16:2215–2222
Fogueri U, Cheungapasitporn W, Bourne D et al (2019) Rituximab exhibits altered pharmacokinetics in patients with membranous nephropathy. Ann Pharmacother 53:357–363
Counsilman CE, Jol-van der Zijde CM, Stevens J et al (2015) Pharmacokinetics of rituximab in a pediatric patient with therapy-resistant nephrotic syndrome. Pediatr Nephrol 30:1367–1370
Stahl K, Duong M, Schwarz A et al (2017) Kinetics of rituximab excretion into urine and peritoneal fluid in two patients with nephrotic syndrome. Case Rep Nephrol 2017:1372859
Yonezawa A, Otani Y, Kitano T et al (2019) Concentration and glycoform of rituximab in plasma of patients with b cell non-Hodgkin’s lymphoma. Pharm Res 36:82
Stein C, Burtey S, Mancini J et al (2021) Acute kidney injury in patients treated with anti-programmed death receptor-1 for advanced melanoma: a real-life study in a single-centre cohort. Nephrol Dial Transplant 36:1664–1674
Seethapathy H, Zhao S, Chute DF et al (2019) The incidence, causes, and risk factors of acute kidney injury in patients receiving immune checkpoint inhibitors. Clin J Am Soc Nephrol 14:1692–1700
Meraz-Muñoz A, Amir E, Ng P et al (2020) Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes. J Immunother Cancer 8:e000467
García-Carro C, Bolufer M, Bury R et al (2022) Acute kidney injury as a risk factor for mortality in oncological patients receiving checkpoint inhibitors. Nephrol Dial Transplant 37:887–894
Kitchlu A, Fingrut W, Avila-Casado C et al (2017) Nephrotic syndrome with cancer immunotherapies: a report of 2 cases. Am J Kidney Dis 70:581–585
Zheng K, Qiu W, Wang H et al (2020) Clinical recommendations on diagnosis and treatment of immune checkpoint inhibitor-induced renal immune-related adverse events. Thorac Cancer 11:1746–1751
Cortazar FB, Marrone KA, Troxell ML et al (2016) Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int 90:638–647
Cortazar FB, Kibbelaar ZA, Glezerman IG et al (2020) Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study. J Am Soc Nephrol 31:435–446
Perazella MA, Shirali AC (2018) Nephrotoxicity of cancer immunotherapies: past, present and future. J Am Soc Nephrol 29:2039–2052
Perazella MA, Shirali AC (2020) Immune checkpoint inhibitor nephrotoxicity: what do we know and what should we do? Kidney Int 97:62–74
Sury K, Perazella MA, Shirali AC (2018) Cardiorenal complications of immune checkpoint inhibitors. Nat Rev Nephrol 14:571–588
Cassol C, Satoskar A, Lozanski G et al (2019) Anti-PD-1 immunotherapy may induce interstitial nephritis with increased tubular epithelial expression of PD-L1. Kidney Int Rep 4:1152–1160
Fadel F, El Karoui K, Knebelmann B (2009) Anti-CTLA4 antibody-induced lupus nephritis. N Engl J Med 361:211–212
Mamlouk O, Selamet U, Machado S et al (2019) Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience. J Immunother Cancer 7:2
Kishi S, Minato M, Saijo A et al (2018) IgA nephropathy after nivolumab therapy for postoperative recurrence of lung squamous cell carcinoma. Intern Med 57:1259–1263
Mo H, Yau D, Mirshahidi H et al (2020) AA amyloidosis associated with pulmonary squamous cell carcinoma treated with chemoradiation and immune checkpoint inhibitor therapy. Pathol Int 70:303–305
Kitchlu A, Jhaveri KD, Wadhwani S et al (2021) A systematic review of immune checkpoint inhibitor-associated glomerular disease. Kidney Int Rep 6:66–77
Espi M, Teuma C, Novel-Catin E et al (2021) Renal adverse effects of immune checkpoints inhibitors in clinical practice: ImmuNoTox study. Eur J Cancer 147:29–39
Wanchoo R, Karam S, Uppal NN et al (2017) Adverse renal effects of immune checkpoint inhibitors: a narrative review. Am J Nephrol 45:160–169
Sise ME, Seethapathy H, Reynolds KL (2019) Diagnosis and management of immune checkpoint inhibitor-associated renal toxicity: illustrative case and review. Oncologist 24:735–742
Robert C (2020) A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun 11:3801
Li H, Xu J, Bai Y et al (2021) Nephrotoxicity in patients with solid tumors treated with anti-PD-1/PD-L1 monoclonal antibodies: a systematic review and meta-analysis. Investig New Drugs 39:860–870
Perazella MA, Sprangers B (2019) AKI in patients receiving immune checkpoint inhibitors. Clin J Am Soc Nephrol 14:1077–1079
Gupta S, Cortazar FB, Riella LV et al (2020) Immune checkpoint inhibitor nephrotoxicity: update 2020. Kidney360 1:130–140
Ubara Y, Kawaguchi T, Nagasawa T et al (2021) Kidney biopsy guidebook 2020 in Japan. Clin Exp Nephrol 25:325–364
Schneider BJ, Naidoo J, Santomasso BD et al (2021) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol 39:4073–4126
Horvat TZ, Adel NG, Dang TO et al (2015) Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol 33:3193–3198
Schadendorf D, Wolchok JD, Hodi FS et al (2017) Efficacy and Safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: a pooled analysis of randomized phase II and III trials. J Clin Oncol 35:3807–3814
Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378:158–168
Oleas D, Bolufer M, Agraz I et al (2021) Acute interstitial nephritis associated with immune checkpoint inhibitors: a single-centre experience. Clin Kidney J 14:1364–1370
Osa A et al (2018) Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients. JCI. Insight. 3:e59125
Lapman S, Whittier WL, Parikh R et al (2020) Immune checkpoint inhibitor-associated renal amyloid A amyloidosis: a case series and review of the literature. J Onco-Nephrol 4:52–58
Acknowledgements
This article is the secondary publication from the Japanese version by the Japanese Society of Nephrology (JSN), Japan Society of Clinical Oncology (JSCO), Japanese Society of Medical Oncology (JSMO), and The Japanese Society of Nephrology and Pharmacotherapy (JSNP) that was published Lifescience publishers Co Ltd, Tokyo, Japan, with permission. We greatly thank other guideline committee members for peer reviews and external review teams from JSN, JSCO, JSMO, JSNP, and the Japanese Society for Dialysis Therapy for their suggestive advice and cooperation. We also thank Toshio Morizane (Japan Council for Quality Health Care), Takeo Nakayama (Department of Health Informatics, School of Public Health, Kyoto University Graduate School of Medicine), and Shigeo Horie (Department of Urology, Juntendo University Faculty of Medicine) for an advisor, Naoki Kashihara (Kawasaki Medical School), Mototsugu Oya (Keio University School of Medicine), Hirokazu Okada (Saitama Medical University), and Masaomi Nangaku (The University of Tokyo) for supervisors of the guideline, Takashi Yokoo (JSN academic committee chairman, Jikei University School of Medicine) and Kengo Furuichi (JSN academic committee vice chairman, Kanazawa Medical University School of Medicine) for observers, Eiichiro Kanda (Kawasaki Medical School) and Takaaki Suzuki (Nara Medical University Library) for systematic literature searching, Hitoshi Watanabe (Lifescience, Co. Ltd.) for editing the Japanese version of the guidelines, office staffs of JSN, JSCO, JSMO, and JSNP, and Yasuhiro Komatsu (Gunma University) for helpful supports.
Author information
Authors and Affiliations
Consortia
Corresponding author
Ethics declarations
Conflict of interest
Y.A has received honoraria from Chugai Pharmaceutical Co., Ltd., Bayer Holding Ltd., and research funding from Chugai Pharmaceutical Co., Ltd., Geo Holdings Corporation, and BeiGene, Ltd. H.N has received honoraria from MSD K.K., Astellas pharma Inc., and Merck Biopharma Co., Ltd., research fundings from Chugai Pharmaceutical Co. Ltd., and a scholarship donation from Bayer AG. E.S has received honoraria from Pfizer Japan Inc., Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Novartis Pharmaceuticals Corporation, and Janssen Pharmaceutical K.K. K.M has received honoraria from MSD, Kyowa Kirin Co., Ltd., and Chugai-Pharmaceutical Co., Ltd., and research fundings from DAIICHI SANKYO COMPANY, MSD, Eli Lilly Japan K.K, Gilead Sciences, and Eisai Co., Ltd. Y.F has received honoraria from AstraZeneca, Bristol-Myers Squibb Company, Chugai-Pharmaceutical Co., Ltd., DAIICHI SANKYO COMPANY, Micron, MSD, and ONO PHARMACEUTICAL CO., LTD., and research fundings from Abbvie, Amgen, AnHeart, AstraZeneca, Bristol-Myers Squibb Company, Chugai-Pharmaceutical Co., Ltd., Eli Lilly Japan K.K, Incyte, and MSD. T.K has received honoraria from Chugai, AstraZeneca and Sysmex, and research funding from PACT Pharma, Chugai, Daiichi-Sankyo, Novartis, Eli Lilly, Pfizer, Janssen Pharmaceutical K.K., Zymworks, and Takeda Pharmaceutical Company Limited. H.K has received honoraria from Astellas Pharma Inc, Takeda Pharmaceutical Company Limited, Bayer AG, and Janssen Pharmaceutical K.K., and scholarship donations from Takeda Pharmaceutical Company Limited and Bayer AG. T. K received honoraria from AstraZeneca. J.H has received honoraria from Kyowa Kirin Co., Ltd., Mitsubishi Tanabe Pharma, Ono Pharm, AstraZeneca and Astellas Pharma Inc, and a research grant from Otsuka Pharmaceutical Co., Ltd. M. Yanagita has received honoraria from Astellas Pharma Inc, AstraZeneca, Kyowa Kirin Co., Ltd., Chugai-Pharmaceutical Co., Ltd., Bayer AG, and Mitsubishi Tanabe Pharma, and research grants from Mitsubishi Tanabe Pharma, Boehringer Ingelheim International GmbH, and scholarship donations from Kyowa Kirin Co., Ltd., Chugai-Pharmaceutical Co., Ltd., and Mitsubishi Tanabe Pharma. The other authors declare no potential conflicts of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Ando, Y., Nishiyama, H., Shimodaira, H. et al. Chapter 3: Management of kidney injury caused by cancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022. Int J Clin Oncol 28, 1315–1332 (2023). https://doi.org/10.1007/s10147-023-02382-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10147-023-02382-2